{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T16:09:11Z","timestamp":1785427751921,"version":"3.56.0"},"reference-count":176,"publisher":"Informa UK Limited","issue":"1","funder":[{"name":"funded"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Metabolism &amp; Toxicology"],"published-print":{"date-parts":[[2018,1,2]]},"DOI":"10.1080\/17425255.2018.1416093","type":"journal-article","created":{"date-parts":[[2017,12,10]],"date-time":"2017-12-10T22:10:47Z","timestamp":1512943847000},"page":"59-82","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":45,"title":["Pharmacokinetics and pharmacogenetics of anti-tubercular drugs: a tool for treatment optimization?"],"prefix":"10.1080","volume":"14","author":[{"given":"Ilaria","family":"Motta","sequence":"first","affiliation":[{"name":",","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Calcagno","sequence":"additional","affiliation":[{"name":",","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Bonora","sequence":"additional","affiliation":[{"name":",","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2017,12,18]]},"reference":[{"key":"e_1_3_3_3_1","unstructured":"[Cited 2017 Dec 12]. Available from: http:\/\/www.who.int\/mediacentre\/factsheets\/fs104\/en\/."},{"key":"e_1_3_3_4_1","unstructured":"http:\/\/www.who.int\/tb\/post2015_strategy\/en\/."},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1413919"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200210-1125OC"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)00070-0"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60359-9"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2011.12.001"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/307150"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.180"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(12)70264-5"},{"key":"e_1_3_3_13_1","unstructured":"WHO Treatment guidelines for drug-resistant tuberculosis 2016 Update - PubMed - NCBI [Internet]. [cited 2017 Jan 22]. Available from: https:\/\/www-ncbi-nlm-nih-gov.offcampus.dam.unito.it\/pubmed\/27748093."},{"key":"e_1_3_3_14_1","unstructured":"[Cited 2017 Dec 13]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02342886?term=pa-824+moxifloxacin&rank=2"},{"key":"e_1_3_3_15_1","unstructured":"TB Alliance. NC-005 trial [Internet]. [Cited 2017 Dec 13]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02193776?term=bedaquiline&rank=8."},{"key":"e_1_3_3_16_1","unstructured":"Conradie F Diacon Andreas H Daniel E et al. THE NIX-TB TRIAL OF PRETOMANID BEDAQUILINE AND LINEZOLID TO TREAT XDR-TB. 2017. [Cited 2017 Dec 13]. Available from: http:\/\/www.croiconference.org\/sessions\/nix-tb-trial-pretomanid-bedaquiline-and-linezolid-treat-xdr-tb."},{"key":"e_1_3_3_17_1","first-page":"160","volume-title":"The World Health Organization. Treatment of tuberculosis: guidelines [Internet]","author":"WHO","year":"2010","unstructured":"WHO. The World Health Organization. Treatment of tuberculosis: guidelines [Internet]. 4th ed. 2010;160. [Cited 2017 Dec 13]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK138741\/#ch2.s3.","edition":"4"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.29.12.1468"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03931-14"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2014.895813"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01533-06"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.7.2118-2124.2003"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2466-1-2"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jit352"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02468-12"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1086\/599040"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku210"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00269-11"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200262150-00001"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01345-13"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.4.1170-1177.2006"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid1610.100374"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12544"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2007.04.007"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.3343\/alm.2016.36.5.489"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.2174\/138161211797470174"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-014-0222-8"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00756-15"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00341-15"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2015.06.008"},{"key":"e_1_3_3_41_1","unstructured":"World Health Organization (WHO). Global Tuberculosis Report 2016 [Internet]. [cited 2017 Apr 17]. Available from: http:\/\/apps.who.int\/iris\/bitstream\/10665\/250441\/1\/9789241565394-eng.pdf?ua=1."},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1586\/17476348.2016.1166960"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1507062"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1602291"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.115.1.12"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir184"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201407-1264OC"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-016-1790-x"},{"key":"e_1_3_3_49_1","unstructured":"Boeree M Hoelscher M. High-dose rifampin SQ109 and moxifloxacin for treating TB: the PanACEA MAMS-TB trial. Presented at the Conference on Retroviruses and Opportunistic Infections 2015 Feb 25; Seattle. abstract. No Title."},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.120.5.1520"},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2014.12.027"},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01474-06"},{"key":"e_1_3_3_53_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01830-15"},{"key":"e_1_3_3_54_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05792-11"},{"key":"e_1_3_3_55_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200342090-00003"},{"key":"e_1_3_3_56_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000944"},{"key":"e_1_3_3_57_1","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/22.Supplement_1.S15"},{"key":"e_1_3_3_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)11467-8"},{"key":"e_1_3_3_59_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200208-951OC"},{"key":"e_1_3_3_60_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314210"},{"key":"e_1_3_3_61_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1104875"},{"key":"e_1_3_3_62_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis461"},{"key":"e_1_3_3_63_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201410-1843OC"},{"key":"e_1_3_3_64_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01918-13"},{"key":"e_1_3_3_65_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200311-1612OC"},{"key":"e_1_3_3_66_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw566"},{"key":"e_1_3_3_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)09742-8"},{"key":"e_1_3_3_68_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2958.2006.05467.x"},{"key":"e_1_3_3_69_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/34.3.313"},{"key":"e_1_3_3_70_1","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.156.3.9609132"},{"key":"e_1_3_3_71_1","doi-asserted-by":"publisher","DOI":"10.1099\/00222615-46-10-847"},{"key":"e_1_3_3_72_1","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1126\/science.8284673","article-title":"inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis","volume":"263","author":"Banerjee A","year":"1994","unstructured":"Banerjee A, Dubnau E, Quemard A, et al. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science [Internet]. 1994 [cited 2017 Apr 13];263:227\u2013230. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/8284673.","journal-title":"Science [Internet]"},{"key":"e_1_3_3_73_1","first-page":"262","article-title":"Should isoniazid be used in retreatment of tuberculosis despite acquired isoniazid resistance?","volume":"123","author":"Moulding TS","year":"1981","unstructured":"Moulding TS. Should isoniazid be used in retreatment of tuberculosis despite acquired isoniazid resistance? Am Rev Respir Dis [Internet]. 1981 [cited 2017 Apr 13];123:262\u2013264. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/6784621.","journal-title":"Am Rev Respir Dis [Internet]"},{"key":"e_1_3_3_74_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-007-0257-9"},{"key":"e_1_3_3_75_1","first-page":"139","article-title":"A randomised controlled trial of high-dose isoniazid adjuvant therapy for multidrug-resistant tuberculosis","volume":"12","author":"Katiyar SK","year":"2008","unstructured":"Katiyar SK, Bihari S, Prakash S, et al. A randomised controlled trial of high-dose isoniazid adjuvant therapy for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis [Internet]. 2008 [cited 2017 Apr 13];12:139\u2013145. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/18230245.","journal-title":"Int J Tuberc Lung Dis [Internet]"},{"key":"e_1_3_3_76_1","first-page":"489","volume-title":"Mand. Douglas, Bennett\u2019s princ. pract. infect. dis","author":"Wallace RJGDE","year":"2005","unstructured":"Wallace RJGDE. Antimycobacterial agents. Mandell GL, Bennett JE, Dolin R, eds. Mand. Douglas, Bennett\u2019s princ. pract. infect. dis. 6th ed. New York. Elsevier. 2005. p. 489\u2013499.","edition":"6"},{"key":"e_1_3_3_77_1","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1183\/09031936.93.01090807","article-title":"Interaction between allopurinol and pyrazinamide","volume":"1","author":"Lacroix C","year":"1988","unstructured":"Lacroix C, Guyonnaud C, Chaou M, et al. Interaction between allopurinol and pyrazinamide. Eur Respir J [Internet]. 1988 [cited 2017 Jan 29];1:807\u2013811. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/3229478.","journal-title":"Eur Respir J [Internet]"},{"key":"e_1_3_3_78_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03085-15"},{"key":"e_1_3_3_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tube.2010.03.005"},{"key":"e_1_3_3_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)62002-X"},{"key":"e_1_3_3_81_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0133869"},{"key":"e_1_3_3_82_1","doi-asserted-by":"publisher","DOI":"10.1111\/1469-0691.12696"},{"key":"e_1_3_3_83_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40520-015-0357-9"},{"key":"e_1_3_3_84_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.11.2484"},{"key":"e_1_3_3_85_1","first-page":"1360","article-title":"Pharmacokinetics of ethambutol in children and adults with tuberculosis","volume":"8","author":"Zhu M","year":"2004","unstructured":"Zhu M, Burman WJ, Starke JR, et al. Pharmacokinetics of ethambutol in children and adults with tuberculosis. Int J Tuberc Lung Dis [Internet]. 2004 [cited 2017 Jan 29];8:1360\u20131367. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/15581206.","journal-title":"Int J Tuberc Lung Dis [Internet]"},{"key":"e_1_3_3_86_1","unstructured":"Implementing tuberculosis diagnostics: a policy framework (WHO\/HTM\/TB\/2015.11) [Internet]. IGeneva World Heal. Organ. 2015. [Cited 2017 Dec 13]. Available from http:\/\/apps.who.int\/iris\/bitstream\/10665\/162712\/1\/9789241508612_eng.pdf."},{"key":"e_1_3_3_87_1","unstructured":"Mandell\u00a0GL \u00a0Bennett\u00a0JE \u00a0Dolin\u00a0R eds.\u00a0Mandell. Douglas Bennett\u2019s princ. pract. infect. dis.\u00a07th\u00a0ed.\u00a0New York.\u00a02009."},{"key":"e_1_3_3_88_1","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.15.0884"},{"key":"e_1_3_3_89_1","doi-asserted-by":"publisher","DOI":"10.1586\/14787210.1.3.371"},{"key":"e_1_3_3_90_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1407426"},{"key":"e_1_3_3_91_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1315817"},{"key":"e_1_3_3_92_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01621-06"},{"key":"e_1_3_3_93_1","doi-asserted-by":"publisher","DOI":"10.1086\/521894"},{"key":"e_1_3_3_94_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00506-13"},{"key":"e_1_3_3_95_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01117-15"},{"key":"e_1_3_3_96_1","doi-asserted-by":"publisher","DOI":"10.2174\/1389200215666140605130935"},{"key":"e_1_3_3_97_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200806-892OC"},{"key":"e_1_3_3_98_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e3181cc6d6f"},{"key":"e_1_3_3_99_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.27.3.476"},{"key":"e_1_3_3_100_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2015.11.012"},{"key":"e_1_3_3_101_1","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0080-2015"},{"key":"e_1_3_3_102_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tube.2004.04.001"},{"key":"e_1_3_3_103_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01204-07"},{"key":"e_1_3_3_104_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00898-06"},{"key":"e_1_3_3_105_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200711-1736OC"},{"key":"e_1_3_3_106_1","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1093\/jac\/dku504","article-title":"Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug","volume":"70","author":"Svensson EM","year":"2014","unstructured":"Svensson EM, Murray S, Karlsson MO, et al. Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug. J Antimicrob Chemother [Internet]. 2014 [cited 2017 Jan 28];70:1106\u20131114. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25535219.","journal-title":"J Antimicrob Chemother [Internet]"},{"key":"e_1_3_3_107_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsb.2006.08.015"},{"key":"e_1_3_3_108_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S60923"},{"key":"e_1_3_3_109_1","volume-title":"The use of delamanid in the treatment of multidrug-resistant tuberculosis","unstructured":"The use of delamanid in the treatment of multidrug-resistant tuberculosis. Interim policy guidance. World Health Organization.WHO 2014."},{"key":"e_1_3_3_110_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)00047-5"},{"key":"e_1_3_3_111_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00637-2016"},{"key":"e_1_3_3_112_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00849-10"},{"key":"e_1_3_3_113_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61080-0"},{"key":"e_1_3_3_114_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200206-626OC"},{"key":"e_1_3_3_115_1","first-page":"879","article-title":"Public Health Service Cooperative trial of three rifampin-isoniazid regimens in treatment of pulmonary tuberculosis","volume":"119","author":"Long MW","year":"1979","unstructured":"Long MW, Snider DE, Farer LSUS. Public Health Service Cooperative trial of three rifampin-isoniazid regimens in treatment of pulmonary tuberculosis. Am Rev Respir Dis [Internet]. 1979 [cited 2016 Jun 24];119:879\u2013894. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/110184.","journal-title":"Am Rev Respir Dis [Internet]"},{"key":"e_1_3_3_116_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200140050-00002"},{"key":"e_1_3_3_117_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200510-1666ST"},{"key":"e_1_3_3_118_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.3.5770.343"},{"key":"e_1_3_3_119_1","doi-asserted-by":"publisher","DOI":"10.1086\/420742"},{"key":"e_1_3_3_120_1","first-page":"622","article-title":"Hearing loss and nephrotoxicity in long-term aminoglycoside treatment in patients with tuberculosis","volume":"6","author":"De Jager P","year":"2002","unstructured":"De Jager P, Van Altena R. Hearing loss and nephrotoxicity in long-term aminoglycoside treatment in patients with tuberculosis. Int J Tuberc Lung Dis [Internet]. 2002 [cited 2017 Apr 14];6:622\u2013627. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/12102302.","journal-title":"Int J Tuberc Lung Dis [Internet]"},{"key":"e_1_3_3_121_1","first-page":"e01400","article-title":"Reduced chance of hearing loss associated with therapeutic drug monitoring of aminoglycosides in the treatment of multidrug-resistant tuberculosis","volume":"61","author":"van Altena R","year":"2017","unstructured":"van Altena R, Dijkstra JA, van der Meer ME, et al. Reduced chance of hearing loss associated with therapeutic drug monitoring of aminoglycosides in the treatment of multidrug-resistant tuberculosis. Antimicrob Agents Chemother [Internet]. 2017 [cited 2017 Apr 14];61:e01400\u201316. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28069654.","journal-title":"Antimicrob Agents Chemother [Internet]"},{"key":"e_1_3_3_122_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(02)01476-6"},{"key":"e_1_3_3_123_1","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2015-207245"},{"key":"e_1_3_3_124_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc053428"},{"key":"e_1_3_3_125_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/49.4.593"},{"key":"e_1_3_3_126_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1482"},{"issue":"3","key":"e_1_3_3_127_1","first-page":"S440","article-title":"Adverse effects of rifampin","volume":"5","author":"Grosset J","unstructured":"Grosset J, Leventis S. Adverse effects of rifampin. Rev Infect Dis [Internet]. [cited 2016 Jun 21];5 Suppl 3: S440\u201350. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/6356277.","journal-title":"Rev Infect Dis [Internet]"},{"key":"e_1_3_3_128_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-199512010-00001"},{"key":"e_1_3_3_129_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01833-10"},{"key":"e_1_3_3_130_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1681.2007.04798.x"},{"key":"e_1_3_3_131_1","first-page":"75","article-title":"SLCO1B1 *15 haplotype is associated with rifampin-induced liver injury","volume":"6","author":"Li L-M","year":"2012","unstructured":"Li L-M, Chen L, Deng G-H, et al. SLCO1B1 *15 haplotype is associated with rifampin-induced liver injury. Mol Med Rep [Internet]. 2012 [cited 2016 Jun 19];6:75\u201382. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22562052.","journal-title":"Mol Med Rep [Internet]"},{"key":"e_1_3_3_132_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00353-10"},{"key":"e_1_3_3_133_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01195-15"},{"key":"e_1_3_3_134_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt036"},{"key":"e_1_3_3_135_1","doi-asserted-by":"publisher","DOI":"10.1080\/10915810600746023"},{"key":"e_1_3_3_136_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-012-1429-9"},{"key":"e_1_3_3_137_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2015.11.044"},{"key":"e_1_3_3_138_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc0806396"},{"key":"e_1_3_3_139_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2007.05207.x"},{"key":"e_1_3_3_140_1","doi-asserted-by":"publisher","DOI":"10.2147\/PGPM.S15454"},{"key":"e_1_3_3_141_1","first-page":"622","article-title":"NAT2 and CYP2E1 polymorphisms and susceptibility to first-line anti-tuberculosis drug-induced hepatitis","volume":"14","author":"Lee S-W","year":"2010","unstructured":"Lee S-W, Chung LS-C, Huang -H-H, et al. NAT2 and CYP2E1 polymorphisms and susceptibility to first-line anti-tuberculosis drug-induced hepatitis. Int J Tuberc Lung Dis [Internet]. 2010 [cited 2016 Jun 24];14:622\u2013626. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20392357.","journal-title":"Int J Tuberc Lung Dis [Internet]"},{"key":"e_1_3_3_142_1","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S1665-2681(19)31302-X","article-title":"Association of GST null genotypes with anti-tuberculosis drug induced hepatotoxicity in Western Indian population","volume":"12","author":"Gupta VH","unstructured":"Gupta VH, Singh M, Amarapurkar DN, et al. Association of GST null genotypes with anti-tuberculosis drug induced hepatotoxicity in Western Indian population. Ann Hepatol [Internet]. [cited 2016 Jun 22];12:959\u2013965. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24114827.","journal-title":"Ann Hepatol [Internet]"},{"key":"e_1_3_3_143_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-015-0862-7"},{"key":"e_1_3_3_144_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku478"},{"key":"e_1_3_3_145_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw471"},{"key":"e_1_3_3_146_1","doi-asserted-by":"publisher","DOI":"10.1038\/ejcn.2015.37"},{"key":"e_1_3_3_147_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00060414"},{"key":"e_1_3_3_148_1","doi-asserted-by":"publisher","DOI":"10.1086\/651686"},{"key":"e_1_3_3_149_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu674"},{"key":"e_1_3_3_150_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.11.4473-4475.2004"},{"key":"e_1_3_3_151_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01193-15"},{"key":"e_1_3_3_152_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ477"},{"key":"e_1_3_3_153_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.129"},{"key":"e_1_3_3_154_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv439"},{"key":"e_1_3_3_155_1","doi-asserted-by":"publisher","DOI":"10.1086\/598336"},{"key":"e_1_3_3_156_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt483"},{"key":"e_1_3_3_157_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv447"},{"key":"e_1_3_3_158_1","doi-asserted-by":"publisher","DOI":"10.1086\/507543"},{"key":"e_1_3_3_159_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00447-09"},{"key":"e_1_3_3_160_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.06059-11"},{"key":"e_1_3_3_161_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-017-2226-y"},{"key":"e_1_3_3_162_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05208-11"},{"key":"e_1_3_3_163_1","doi-asserted-by":"publisher","DOI":"10.1021\/ac1029049"},{"key":"e_1_3_3_164_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3937"},{"key":"e_1_3_3_165_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijmyco.2016.09.061"},{"key":"e_1_3_3_166_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tube.2006.12.001"},{"key":"e_1_3_3_167_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.33.8.1255"},{"key":"e_1_3_3_168_1","first-page":"933","article-title":"Uptake of antibiotics by human alveolar macrophages","volume":"129","author":"Hand WL","year":"1984","unstructured":"Hand WL, Corwin RW, Steinberg TH, et al. Uptake of antibiotics by human alveolar macrophages. Am Rev Respir Dis [Internet] 1984 [cited 2016 Jun 24];129:933\u2013937. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/6732052.","journal-title":"Am Rev Respir Dis [Internet]"},{"key":"e_1_3_3_169_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro3200"},{"key":"e_1_3_3_170_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv148"},{"key":"e_1_3_3_171_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2007.07.005"},{"key":"e_1_3_3_172_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13196"},{"key":"e_1_3_3_173_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0065806"},{"key":"e_1_3_3_174_1","doi-asserted-by":"publisher","DOI":"10.1086\/346053"},{"key":"e_1_3_3_175_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05561-11"},{"key":"e_1_3_3_176_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-198916020-00002"},{"key":"e_1_3_3_177_1","unstructured":"Early termination of a pk study between dolutegravir and weekly isoniazid\/Rifapentine | CROI Conference [Internet]. [cited 2017 Apr 19]. Available from: http:\/\/www.croiconference.org\/sessions\/early-termination-pk-study-between-dolutegravir-and-weekly-isoniazidrifapentine."},{"key":"e_1_3_3_178_1","unstructured":"Liverpool HIV Interactions [Internet]. [cited 2017 Apr 18]. Available from: http:\/\/www.hiv-druginteractions.org\/."}],"container-title":["Expert Opinion on Drug Metabolism &amp; Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17425255.2018.1416093","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T21:24:54Z","timestamp":1772745894000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17425255.2018.1416093"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,18]]},"references-count":176,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1,2]]}},"alternative-id":["10.1080\/17425255.2018.1416093"],"URL":"https:\/\/doi.org\/10.1080\/17425255.2018.1416093","relation":{},"ISSN":["1742-5255","1744-7607"],"issn-type":[{"value":"1742-5255","type":"print"},{"value":"1744-7607","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,18]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2016-06-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-12-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-12-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}